Cardiovascular protective effects of synthetic isoflavone derivatives in apolipoprotein E-deficient mice

被引:22
|
作者
Jiang, F [1 ]
Jones, GT
Husband, AJ
Dusting, GJ
机构
[1] Univ Melbourne, Howard Florey Inst, Melbourne, Vic 3010, Australia
[2] Univ Otago Sch Med, Dept Surg, Vasc Res Grp, Dunedin, New Zealand
[3] Novogen Ltd, Sydney, NSW, Australia
关键词
antioxidant; apolipoprotein E-deficient; atherosclerosis; endothelial dysfunction; endothelium-dependent vasorelaxation; flavonoids; hyperlipidemia; isoflavone; nitric oxide; oxidative stress;
D O I
10.1159/000071891
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Dietary flavonoids are thought to protect against cardiovascular disease. We have studied the effects of bioactive isoflavone metabolites on hyperlipidemia, endothelial dysfunction and the development of atherosclerotic lesions in apolipoprotein E-deficient (apoE(0)) mice fed a Western high-fat diet. Supplementation with dihydrodaidzein (DiD), dehydroequol (DeE) (both 25 mg kg(-1). day(-1)) and their combination (D/D; 12.5 mg kg(-1.)day(-1) for each) for 24 weeks reduced plasma high-density lipoprotein (HDL) and non-HDL cholesterol. D/D also reduced the triglyceride level. In the abdominal aorta of apoE(0) mice, these compounds significantly increased endothelial nitric oxide (NO)-mediated vasorelaxations induced by acetylcholine, but had a minor effect on relaxations induced by the NO donor S-nitroso-N-acetylpenicillamine. Isoflavone treatment for 24 weeks had no effect on the total area of atherosclerotic plaques in the whole aorta, but DeE reduced the plaque thickness in the aortic arch by 29%, although this did not reach statistical significance. The endothelial dysfunction in apoE(0) mice is associated with hyperlipidemia and increased vascular oxidative stress measured as increased superoxide production. Both isoflavones have superoxide-scavenging activities in vitro. We suggest that chronic supplementation with bioactive isoffavone metabolites may protect endothelial NO function in apoE(0) mice, through both lipid-lowering and antioxidant actions. Copyright (C) 2003 S. Karger AG, Basel.
引用
收藏
页码:276 / 284
页数:9
相关论文
共 50 条
  • [1] Cardiovascular effects of uremia in apolipoprotein E-deficient mice
    Bro, Susanne
    DANISH MEDICAL BULLETIN, 2009, 56 (04) : 177 - 192
  • [2] Development of Apolipoprotein E-Deficient Mice
    Maeda, Nobuyo
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2011, 31 (09) : 1957 - 1962
  • [3] Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice
    Hayek, T
    Attias, J
    Smith, J
    Breslow, JL
    Keidar, S
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 31 (04) : 540 - 544
  • [4] Atherosclerosis and the protective role played by different proteins in apolipoprotein E-deficient mice
    Rodella, Luigi Fabrizio
    Bonomini, Francesca
    Rezzani, Rita
    Tengattini, Sandra
    Hayek, Tony
    Aviram, Michael
    Keidar, Shlomo
    Coleman, Raymond
    Bianchi, Rossella
    ACTA HISTOCHEMICA, 2007, 109 (01) : 45 - 51
  • [5] Diet and Atherosclerosis in Apolipoprotein E-Deficient Mice
    Imaizumi, Katsumi
    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2011, 75 (06) : 1023 - 1035
  • [6] Renal injury in apolipoprotein E-deficient mice
    Wen, M
    Segerer, S
    Dantas, M
    Brown, PA
    Hudkins, KL
    Goodpaster, T
    Kirk, E
    LeBoeuf, RC
    Alpers, CE
    LABORATORY INVESTIGATION, 2002, 82 (08) : 999 - 1006
  • [7] Hyperphosphorylation of tau in apolipoprotein E-deficient mice
    Genis, I
    Michaelson, DM
    PROGRESS IN ALZHEIMER'S AND PARKINSON'S DISEASES, 1998, 49 : 251 - 256
  • [8] Therapy of Atherosclerosis in Apolipoprotein E-Deficient Mice
    Wang, Min
    Yang, Hua
    Tan, Mengqun
    MOLECULAR THERAPY, 2014, 22 : S231 - S231
  • [9] PHOSPHORYLATION OF TAU IN APOLIPOPROTEIN E-DEFICIENT MICE
    GENIS, I
    GORDON, I
    SEHAYEK, E
    MICHAELSON, DM
    NEUROSCIENCE LETTERS, 1995, 199 (01) : 5 - 8
  • [10] Ocular cytopathy in apolipoprotein E-deficient mice
    Ong, JM
    Rosenberg, SE
    Zorapapel, NC
    Rajeev, B
    Nesburn, AB
    Kenney, MC
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1999, 40 (04) : S920 - S920